Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers.
about
Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and managementMolecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practiceEstablished and emerging targeted therapies in the myelodysplastic syndromes.Automated screening for myelodysplastic syndromes through analysis of complete blood count and cell population data parameters.The challenging world of cytopenias: distinguishing myelodysplastic syndromes from other disorders of marrow failureRisk stratification in myelodysplastic syndromes: is there a role for gene expression profiling?Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.Peroxiredoxin 2 expression is increased in neutrophils of patients with refractory cytopenia with multilineage dysplasia.Cytokine expression patterns and mesenchymal stem cell karyotypes from the bone marrow microenvironment of patients with myelodysplastic syndromes.Discrepancy in diagnosis of primary myelofibrosis between referral and tertiary care centers.Anemia in the Elderly: not Always what it Seems.Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes.Burst-forming unit-erythroid assays to distinguish cellular bone marrow failure disorders.Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management.Tertiary center referral patterns for patients with myelodysplastic syndrome are indicative of age and race disparities: a single-institution experience.Dysplasia has A differential diagnosis: distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors.Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management.Lymphoma diagnosis at an academic centre: rate of revision and impact on patient care.Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes.I walk the line: how to tell MDS from other bone marrow failure conditions.Importance of classical morphology in the diagnosis of myelodysplastic syndrome.Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions.Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome.Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents.Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification.Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.Nuances of Morphology in Myelodysplastic Diseases in the Age of Molecular Diagnostics.Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts.Combined B12 and folate deficiency presenting as an aggressive hematologic malignancy.
P2860
Q26796240-ABBF6DD5-D38A-4067-AAEE-012547EBF26FQ26801573-891782CE-D9B3-4DFF-9003-7C6FED283353Q27016511-81ED1336-4FEE-4ACA-BC00-99C996561952Q30245476-C861ABB3-18E3-419D-85F4-DBDE10FA150AQ30701433-1DB95D55-ABF0-4BB3-94C5-9B695656BACAQ33829778-E6A303A2-ACA0-4B3F-8AE3-E1C2668339C0Q34013786-4186D473-97A0-4902-BECE-46D1D13ED748Q34106883-7D2B7F4B-88FF-478E-A135-7283909A4165Q35174357-6B48CDB0-F8E3-4A24-956C-9567D1BFDE48Q35240550-79046E5A-F6EA-48F2-81F4-23BC18D8505FQ35525312-5FBEA61B-4D56-4002-B976-4E9EE7693256Q36630806-C08C7A4D-A94D-4C83-844D-A09D36EAB949Q36862492-B31FFA49-233A-4375-9EE0-6E7E83751CA9Q37161376-D835D989-D7CD-4CE6-BC0E-D0126ACB501AQ38018571-C84BC9DB-F1FD-4267-8FFC-B9F71EC6D085Q38026071-241CDF12-B841-45CC-84CC-8DF826781DDDQ38046783-46FE82BE-32DA-418B-AF49-280147E239ADQ38181996-BA76D9E3-3011-45C6-ACC3-C8B502ECEEFBQ38201760-9ECB8DBA-4BF0-4B46-8BA9-5D24A87AEA65Q38220788-188B244E-046F-46D8-A173-3DA62BB9A71DQ38235622-1B459CBA-F55C-4975-8BF6-C3403C175E3DQ38471249-85678FFC-F497-42CD-8AF9-AED577DACB42Q38678113-DD2E5A1D-DA28-41BF-A6B1-01A320194219Q38905610-FCCA5055-A9A4-403C-B5BE-8C8CB912F076Q40385613-42D60609-4DB5-499F-A610-3A1D3095DD25Q47189507-C8C3FCD0-7C3F-4A1B-A20B-7800918788F5Q47548041-7EB785CB-E28A-471F-8F17-59DC62334A10Q51804731-4691E3C4-41AF-4256-B81E-4DCFA9C42771Q52803473-718E15AD-16CB-4119-BBD6-D987AE320EDEQ53081738-51CFCD57-F38C-4C64-B739-F79784076D7EQ53602622-4A4C7C81-3819-4885-864A-0A762790968C
P2860
Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Implications of discrepancy in ...... ral and tertiary care centers.
@ast
Implications of discrepancy in ...... ral and tertiary care centers.
@en
type
label
Implications of discrepancy in ...... ral and tertiary care centers.
@ast
Implications of discrepancy in ...... ral and tertiary care centers.
@en
prefLabel
Implications of discrepancy in ...... ral and tertiary care centers.
@ast
Implications of discrepancy in ...... ral and tertiary care centers.
@en
P2860
P50
P1433
P1476
Implications of discrepancy in ...... ral and tertiary care centers.
@en
P2093
Carlos Bueso-Ramos
Kiran Naqvi
P2860
P304
P356
10.1182/BLOOD-2011-03-342642
P407
P50
P577
2011-08-25T00:00:00Z